The Maximal Expected Benefit of SARS-CoV-2 Interventions Among University Students: A Simulation Study Using Latent Class Analysis

Publication date: Nov 03, 2024

Non-pharmaceutical public health measures (PHMs) were central to pre-vaccination e[ff]orts to reduce Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) exposure risk; heterogeneity in adherence placed bounds on their potential e[ff]ectiveness, and correlation in their adoption makes assessing the impact attributable to an individual PHM di[ffi]cult. During the Fall 2020 semester, we used a longitudinal cohort design in a university student population to conduct a behavioral survey of intention to adhere to PHMs, paired with an IgG serosurvey to quantify SARS- CoV-2 exposure at the end of the semester. Using Latent Class Analysis on behavioral survey responses, we identi[fi]ed three distinct groups among the 673 students with IgG samples: 256 (38.04%) students were in the most adherent group, intending to follow all guidelines, 306 (46.21%) in the moderately-adherent group, and 111 (15.75%) in the least-adherent group, rarely intending to follow any measure, with adherence negatively correlated with seropositivity of 25.4%, 32.2% and 37.7%, respectively. Moving all individuals in an SIR model into the most adherent group resulted in a 76-93% reduction in seroprevalence, dependent on assumed assortativity. The potential impact of increasing PHM adherence was limited by the substantial exposure risk in the large proportion of students already following all PHMs.

PDF

Concepts Keywords
Academic Adherence
Ferrari12 Behavioral
Small45 Class
Vaccination Cov
Group
Igg
Infection
Interventions
Lca
Medrxiv
Preprint
Public
Risk
Sars
Students

Semantics

Type Source Name
drug DRUGBANK Coenzyme M
disease IDO host
disease IDO susceptibility
disease MESH influenza
disease IDO immunodeficiency
disease MESH Hepatitis
disease IDO intervention
disease MESH infection
disease MESH emergency
disease IDO blood
drug DRUGBANK Water
disease MESH COVID 19
drug DRUGBANK Isoxaflutole
drug DRUGBANK Sulpiride
drug DRUGBANK Abacavir
drug DRUGBANK Aspartame

Download Document

(Visited 1 times, 1 visits today)